Related Experiment Videos

Cardio classics revisited--focus on the role of candesartan

Maria Leonarda De Rosa1

  • 1University of Naples Federico II, Department of Cardiology, Naples, Italy. marialeonarda.derosa@unina.it

Vascular Health and Risk Management
|December 31, 2010
PubMed

Insights

Angiotensin II receptor blockers (ARBs) effectively reduce cardiovascular disease risk across the continuum of care. Landmark candesartan trials demonstrate ARB benefits in patients at risk, stroke, myocardial infarction, and heart failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a global health crisis, causing significant mortality.
  • Angiotensin II receptor blockers (ARBs) are a class of antihypertensive drugs with established efficacy and safety.
  • The CV continuum model describes the progression of cardiovascular conditions.

Purpose of the Study:

  • To review landmark clinical trials of the ARB candesartan over the past decade.
  • To evaluate the efficacy of ARBs across the full spectrum of cardiovascular disease.
  • To discuss the role of ARBs in various patient populations and ongoing research.

Main Methods:

  • Review of published clinical trials focusing on candesartan.
  • Analysis of data spanning the cardiovascular continuum, from at-risk patients to established conditions.
  • Inclusion of trials addressing stroke, myocardial infarction (MI), and heart failure (HF).

Main Results:

  • ARBs, including candesartan, demonstrate significant benefits in reducing cardiovascular risk.
  • Evidence supports ARB use across diverse patient populations and stages of cardiovascular disease.
  • Ongoing trials may further expand the application of ARBs in managing cardiovascular conditions.

Conclusions:

  • ARBs are crucial agents in managing cardiovascular disease across its continuum.
  • Candesartan has a well-established role in reducing cardiovascular events.
  • Continued research will likely broaden the therapeutic applications of ARBs.

Keywords:
angiotensin II receptor blockerscandesartancardiovascular disease

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...